Developing optimized curcumin formulations with improved

The gap

Evidence profile

Stated in the inline gaps and limitations and conclusions sections of the source papers, classified as general, spanning 3 journals.

Supporting evidence — 3 representative gaps

• Molecular Docking Evaluation of Curcumin, Ursolic Acid, Quercetin, Berberine, and Andrographolide Against HIV-1 Reverse Transcriptase and Protease (2026) · International Journal of Science, Strategic Management and Technology · doi

  9 Study Limitations Several limitations of this study should be acknowledged. Bioavailability enhancement strategies should be explored for curcumin and berberine, including nanoparticle formulations, liposomal encapsulation, phytosome complexes, and co-administration with piperine. First, molecular docking provides computational predictions of binding affinity but does not account for protein flexibility, solvent effects, or entropic contributions.

  generalstated in inline gapsevidence 5/5
  Keywords: limitations several acknowledged bioavailability enhancement strategies explored curcumin berberine including nanoparticle formulations liposomal encapsulation phytosome
• Nano-Encapsulated Curcumin Improves Ovarian and Uterine Recovery from Cadmium Toxicity in Rats (2026) · The Open Biomedical Engineering Journal · doi

  Future studies should address these limitations to further validate the therapeutic potential and safety of nano-curcumin formulations. Second, the long-term safety profile and potential toxicological effects of the nanoparticle Furthermore, delivery system were not molecular mechanisms underlying the improved protective efficacy of nano-curcumin were not fully elucidated.

  generalstated in limitationsevidence 5/5
  Keywords: potential safety nano curcumin future address limitations further validate therapeutic formulations second long term profile
• Curcumin as a ceramide metabolism-targeting agent: Molecular mechanisms and therapeutic implications in cancer (2026) · Molecular Biology Reports · doi

  Future studies should focus on developing optimized curcumin formulations with improved pharmacokinetics, exploring combinatorial regimens with ceramide analogs or targeted inhibitors, and conducting well-designed clini- cal trials to validate preclinical observations.

  generalstated in conclusionsevidence 4/5
  Keywords: future focus developing optimized curcumin formulations improved pharmacokinetics exploring combinatorial regimens ceramide analogs targeted inhibitors

Questions about this gap